Physician profile
Lisa Sammon
NPI 1710244173
$3,783.31
in general payments reported to CMS, 2019-2025
26 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.57 · 2020: $70.60 · 2021: $12.87 · 2022: $257 · 2023: $635 · 2024: $1,382 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,073 · Honoraria: $175 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,073.20 |
| Honoraria | $175.00 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $474.90 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $406.97 | 2020-2025 | Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $395.55 | 2019-2025 | Dupixent |
| Csl Behring | $384.73 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genentech USA, INC. | $273.08 | 2023-2025 | Xolair |
| Aimmune Therapeutics, INC. | $241.41 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $204.01 | 2019-2025 | |
| Amgen INC. | $193.17 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $177.58 | 2020-2025 | Cuvitru, Eohilia |
| Kaleo, INC. | $152.48 | 2019-2024 | Auvi-Q |
| Abbvie INC. | $125.00 | 2023 | |
| Biocryst US Sales Co., LLC | $123.31 | 2023-2025 | Orladeyo |
| Grifols USA, LLC | $108.40 | 2019-2025 | Xembify |
| Glaxosmithkline, LLC. | $92.19 | 2023-2025 | Nucala, Trelegy Ellipta |
| Pharming Healthcare, INC. | $91.08 | 2023-2025 | Ruconest |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $66.66 | 2019-2025 | |
| Kedrion Biopharma, INC. | $60.99 | 2024-2025 | Gammaked, Kedrab, Koate |
| Ars Pharmaceuticals Operations, INC. | $40.50 | 2025 | Neffy |
| Pfizer INC. | $38.58 | 2025 | |
| Azurity Pharmaceuticals, INC. | $29.15 | 2025 | Alvesco |
| Greer Laboratories, INC. | $26.61 | 2023 | Palforzia |
| Lilly USA, LLC | $25.37 | 2025 | Ebglyss |
| Galderma Laboratories, L.P. | $18.99 | 2025 | Nemluvio |
| Aytu Biopharma, INC. | $18.32 | 2024 | Karbinal |
| Phadia US INC. | $14.28 | 2025 | Immunocap |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Sammon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.